# DESTINY-Gastric02

Source: https://onco.cc/trials/destiny-gastric02/  
OnCo record `destiny-gastric02` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DESTINY-Gastric02 repeated the trastuzumab deruxtecan study in patients from Europe and the United States, after the first trial had been run only in Japan and Korea, and confirmed that the drug produces meaningful responses in HER2-positive stomach cancer after trastuzumab.

## Summary

DESTINY-Gastric01 enrolled only East Asian patients, where stomach cancer is treated differently and diagnosed earlier. DESTINY-Gastric02 was a single-arm phase 2 study in the United States and Europe of trastuzumab deruxtecan in 79 patients with HER2-positive gastric or gastro-oesophageal junction cancer that had progressed on a first-line trastuzumab regimen, with the HER2 status re-confirmed on a fresh biopsy. The primary endpoint was confirmed objective response by independent review.

The study confirmed clinically meaningful and durable responses in a Western population, with a safety profile consistent with the earlier trial, supporting the drug's use outside East Asia. The subtype page notes that the response rate was lower than in the Asian trial.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-17
- Tags: subtype-trials
- Registry id: NCT04014075
- Phase: 2
- Setting: Western patients with HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after a trastuzumab-containing regimen: single-arm trastuzumab deruxtecan
- Sponsor: Daiichi Sankyo
- Enrolled: 79
- Result: Confirmed durable responses to trastuzumab deruxtecan in a Western population after progression on trastuzumab.
- Outcomes: Confirmed objective response by independent central review (registry results, primary analysis): Trastuzumab deruxtecan 38%; Confirmed objective response by independent central review (registry results, later analysis): Trastuzumab deruxtecan 41.8%

## Sources

- ClinicalTrials.gov NCT04014075: https://clinicaltrials.gov/study/NCT04014075

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)
- people: [Eric Van Cutsem](https://onco.cc/people/eric-van-cutsem/)
- key papers: [DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer](https://onco.cc/key-papers/paper-destiny-gastric01-nejm-2020/)

---
JSON: https://onco.cc/api/v1/entities/destiny-gastric02.json